Trial · NCT04897516
Shorter Benznidazole Regimens Compared to the Standard Regimen for Chagas Disease
NCT04897516, Phase 3, Recruiting, Laboratorio Elea Phoenix S.A.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Shorter Benznidazole Regimens Compared to the Standard Regimen for Chagas Disease. Trials, record NCT04897516. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04897516
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Shorter Benznidazole Regimens Compared to the Standard Regimen for Chagas Disease
- NCT number
- NCT04897516
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 300 participants, estimated
- Lead sponsor
- Laboratorio Elea Phoenix S.A.
- Conditions
- Chagas Disease
- Interventions
- Short regimen of benznidazole, Short treatment with benznidazole, Standard treatment with benznidazole
- First posted
- 2021-05-21
- Last updated
- 2023-11-30
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportion of patients with sustained negativation of parasitemia according to the results of qualitative PCR tests | From the end of treatment, and up to 12 months of follow-up from the end of treatment. | Sustained parasitological response will be determined by negative serial qualitative PCR results (two negative PCR results from three DNA extractions from a sample) from the end of treatment with the elimination of sustained parasitaemia until the end of 12 months' follow-up from the end of treatment. |
| Secondary | Proportion of patients with negative parasitemia at 1, 4, 6 and 8 months follow-up form the end of treatment | 1, 4, 6 and 8 months from the end of treatment | Proportion of patients with negative parasitemia at 1, 4, 6 and 8 months follow-up form the end of treatment |
| Secondary | Incidence and severity of adverse events | From the end of treatment, and up to 12 months of follow-up from the end of treatment | Incidence and severity of adverse events |
| Secondary | Incidence of SAEs, Adverse Events of Special Interest (AESIs) and/or adverse events that cause treatment interruption | From the end of treatment, and up to 12 months of follow-up from the end of treatment. | Incidence of SAEs, Adverse Events of Special Interest (AESIs) and/or adverse events that cause treatment interruption |
| Secondary | Descriptions of patients adherence to treatment in each study arm. | 2, 4 and 8 weeks | describing the number of completed treatment in patients vs uncompleted treatment in patients |
| Other | Incidence and severity of adverse events | From the end of treatment, and up to 12 months of follow-up from the end of treatment. | Incidence and severity of adverse events |
| Other | Incidence of SAEs, Adverse Events of Special Interest (AESIs) and/or adverse events that cause treatment interruption | From the end of treatment, and up to 12 months of follow-up from the end of treatment | Incidence of SAEs, Adverse Events of Special Interest (AESIs) and/or adverse events that cause treatment interruption |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 41027700 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04897516
GET https://conductscience.org/api/trials/v1/NCT04897516/registered